Ruihua Xu
Sun Yat-sen University
Emerging Leaders
not ranked
Current Leaders
#488 pts
All-Time Leaders
#22435 pts
Scored by the scientific impact (publications, citations, press) of the trials they lead, weighted by role. First trial 2008. 19 trials as lead/chair. How it works →
Trials led — by scientific impact
A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of Oral HQP1351 in Patients With GIST or Other Solid Tumors.
Phase 1RecruitingAscentage Pharma Group Inc.
4
impact
Chidamide+Sintilimab+Bevacizumab Versus Standard Second-Line Therapy of FOLFIRI+Bevacizumab in Subjects With Advanced Microsatellite Stable (MSS/pMMR) Colorectal Cancer Who Have Failed Oxaliplatin-Containing First-Line Therapy
Phase 3RecruitingSun Yat-sen University
4
impact
Phase II Study of Trastuzumab in Combination With Chemotherapy (Docetaxel Plus Capecitabine) For First Line Treatment of Her2-Positive Advanced Gastric or Gastro-Esophageal Junction Cancer
Phase 2CompletedSun Yat-sen University
4
impact
Tislelizumab Plus Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma: a Phase II, Randomized Trial (EC-CRT-002)
Phase 2ActiveSun Yat-sen University
4
impact
Circulating Tumor DNA as a Prognostic Marker for Postoperative Relapse in Early and Intermediate Stage Colorectal Cancer:A Prospective, Multicenter,Observational, Single-Blinded Controlled Study
N/AUnknownSun Yat-sen UniversityStudy Chair
3
impact
A Multi-Center, Open Label Phase Ib/II Clinical Study to Evaluate JS001 in Patients With Advanced Gastric Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Nasopharyngeal Carcinoma and Head and Neck Squamous Cell Carcinoma
Phase 2UnknownShanghai Junshi Bioscience Co., Ltd.
3
impact
Maintenance Treatment With Capecitabine Versus Observation After First Line Chemotherapy in Patients With Metastatic Colorectal Cancer: a Randomized Phase II Study
Phase 2UnknownSun Yat-sen University
3
impact
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors
Phase 1RecruitingSichuan Baili Pharmaceutical Co., Ltd.
2
impact
A Multi-center, Non-Randomized, Open-Label Phase 2 Basket Clinical Trial to Evaluate ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors
Phase 2RecruitingBeijing InnoCare Pharma Tech Co., Ltd.
2
impact
A Phase III, Randomized, Placebo Controlled, Multicenter, Double-Blind Study Comparing Toripalimab Injection (JS001) Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Recurrent or Metastatic Nasopharyngeal Cancer
Phase 3CompletedShanghai Junshi Bioscience Co., Ltd.
2
impact
An Open-Label, Dose-Finding, Phase I Study in Solid Tumors.
Phase 1CompletedShanghai Miracogen Inc.
1
impact
A Randomized, Open-label, Multi-center, Phase III Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
Phase 3RecruitingShanghai Miracogen Inc.
1
impact
A Single-Arm Registrational Phase III Study of Olverembatinib in the Treatment of Patients With SDH-Deficient Gastrointestinal Stromal Tumor (POLARIS-3)
Phase 3RecruitingAscentage Pharma Group Inc.Study Chair
1
impact
A Clinical Trial of S-1 Plus Cisplatin Versus 5-FU Plus Cisplatin in Patients With Unresectable or Advanced Gastric Cancer
Phase 3UnknownSun Yat-sen University
1
impact
An Open-label, Phase I Trial of SIM1811-03 to Assess the Safety, Efficacy and Pharmacokinetics/Pharmacodynamics in Subjects With Advanced Tumors
Phase 1UnknownJiangsu Simcere Biologics Co., Ltd
1
impact
A Single-arm, Open-label, Phase II Clinical Study of Cetuximab Plus Irinotecan in Patients With NeoRAS Wild-type Metastatic Colorectal Cancer In Third-line Therapy
Phase 2RecruitingSun Yat-sen University
0
impact
A Randomized Phase 2 Clinical Trial Evaluating Sintilimab and Chidamide in Combination With or Without IBI305 in Patients With Standard Treatment Failure of Advanced or Metastatic pMMR/MSS Colorectal Carcinoma
Phase 2UnknownSun Yat-sen University
0
impact
An Open-Label, Phase 1, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CMG901 in Subjects With Advanced Unresectable or Metastatic Solid Tumor
Phase 1CompletedKeymed Biosciences Co.Ltd
0
impact
A Phase III Study to Evaluate the Efficacy and Safety of Fruquintinib in Combination With Paclitaxel Versus Paclitaxel Alone in Second Line Gastric Cancer
Phase 3CompletedHutchison Medipharma Limited
0
impact
0
impact
A Phase I/II Clinical Trial to Evaluate the Safety and Tolerability of JCXH-211 Intratumoral Injection Combined With Anti-PD-1 Antibody IV Infusion in Patients With Malignant Solid Tumors
Phase 2Not Yet RecruitingImmorna Biotherapeutics, Inc.
0
impact
A Phase II, Multicenter, Open Label, Parallel Cohort Clinical Trial to Evaluate the Efficacy and Safety of PM8002 (BNT327) in Combination With Chemotherapy in First Line MSS or MSI-L/pMMR Metastatic Colorectal Cancer
Phase 2Not Yet RecruitingBiotheus Inc.
0
impact
A Multicenter, Open-Label, Phase I/II Clinical Study to Evaluate CM518D1 in the Treatment of Patients With Advanced Solid Tumors
Phase 1RecruitingKeymed Biosciences Co.Ltd
0
impact
A Phase Ib/IIa Clinical Trial Evaluating the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Tumors
Phase 1RecruitingZhejiang Doer Biologics Co., Ltd.
0
impact
Ivonescimab (AK112) Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS/pMMR Metastatic Colorectal Cancer: a Randomized, Controlled, Multicenter Phase II Study
Phase 2Not Yet RecruitingSun Yat-sen University
0
impact
A Phase I, Multicenter, Open-label Study to Evaluate the Safety, Pharmacokinetics, Preliminary Efficacy of KNT-0916 in Subjects with Unresectable or Metastatic Solid Tumors with FGFR2 Alterations
Phase 1Not Yet RecruitingKinoTeck Therapeutics Co., Ltd
0
impact
A Multicenter, Non-randomized, Open-label, Multiple-Dose Phase I Study of NWY001, in Subjects With Advanced Solid Tumors
Phase 1RecruitingChipscreen Biosciences, Ltd.
0
impact
Simmitinib Versus Investigator's Choice of Chemotherapy for Participants With Advanced or Metastatic Oesophageal Squamous Cell Carcinoma : a Randomised, Open-label, Multicentre, Phase 3 Study
Phase 3Not Yet RecruitingShanghai Runshi Pharmaceutical Technology Co., Ltd
0
impact
A Multicenter, Randomized, Controlled Phase II Clinical Study of Comparison of Docetaxel for Injection (Albumin-bound) and Taxotere in Second-line or Above Locally Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma
Phase 2UnknownCSPC ZhongQi Pharmaceutical Technology Co., Ltd.Study Chair
0
impact
Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma
Phase 3RecruitingSun Yat-sen University
0
impact
Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of Injectable BL-M02D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors or Other Solid Tumors
Phase 1ActiveSichuan Baili Pharmaceutical Co., Ltd.
0
impact
A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics of JS107 in Patients With Advanced Solid Tumors
Phase 1UnknownShanghai Junshi Bioscience Co., Ltd.
0
impact
0
impact
An Open-label, Multi-center, Phase I/II Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of MRG003 in Combination With HX008 in Patients With EGFR-positive Advanced Solid Tumors
Phase 2UnknownShanghai Miracogen Inc.
0
impact
A Phase III, Multicenter, Open-label, Randomized Study to Assess the Efficacy and Safety of Cetuximab Plus Capecitabine Versus Cetuximab as Maintenance Treatment Following First-line Induction Treatment With FOLFOX and Cetuximab in Chinese Patients With RAS and BRAF Wild-type Metastatic Colorectal Cancer
Phase 3UnknownSun Yat-sen UniversityStudy Chair
0
impact
A Multicentre, Open-label, Single-arm Phase II Study of HA121-28 Tablets in Advanced Biliary Tract Cancer (BTC)
Phase 2TerminatedCSPC ZhongQi Pharmaceutical Technology Co., Ltd.
0
impact
A Dose Escalation and Dose Expansion Study of WJ01024 to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy for Patients With Advanced Cancer
Phase 1TerminatedSuzhou Junjing BioSciences Co., Ltd.
0
impact
0
impact
A Single-arm, Open-label, Multicenter, Phase II Study of AK104 in Patients With Metastatic Nasopharyngeal Carcinoma Who Have Progressed After At Least 2 Prior Lines of Chemotherapy
Phase 2CompletedAkesoStudy Chair
0
impact
Open, Multicenter, Monotherapy, Phase II Clinical Study of Utidelone Injection in Patients With Advanced or Metastatic Colorectal Cancer After Failure or Intolerability to Second-line Standard Treatment
Phase 2SuspendedBeijing Biostar Pharmaceuticals Co., Ltd.
0
impact
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Compare Toripalimab Injection (JS001) Combined With Standard Chemotherapy Versus Placebo Combined With Standard Chemotherapy in Treatment of Advanced or Metastatic Esophageal Squamous Cell Cancer (ESCC) Without Previous Systemic Chemotherapy
Phase 3CompletedShanghai Junshi Bioscience Co., Ltd.
0
impact
A Multi-center, Open-label, Single Arm, Dose Escalation and Dose Extension Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Advanced Solid Tumors Patients.
Phase 1CompletedHaihe Biopharma Co., Ltd.
0
impact
A Phase I, Open Label, Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SHR7390 Combined With SHR-1210 and SHR3162 in Patients With Advanced Solid Tumors
Phase 1TerminatedJiangsu HengRui Medicine Co., Ltd.
0
impact
Phase IA Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Recombinant Humanized Anti-PD-1 Monoclonal Antibody (JS001) in Patients With Advanced Solid Tumors
Phase 1CompletedShanghai Junshi Bioscience Co., Ltd.
0
impact
A Phase I, Open Label, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SHR7390 in Patients With Advanced Solid Tumors
Phase 1UnknownJiangsu HengRui Medicine Co., Ltd.
0
impact
Phase II Study of Albumin Bound Paclitaxel Plus S-1 as the First Line Chemotherapy in Advanced or Recurrent Gastric Cancer
Phase 2CompletedSun Yat-sen University
0
impact
The Real Clinical Background of Advanced Colorectal Cancer Treatment Situation Survey
N/AUnknownChinese Medical Doctor Association
0
impact
Phase II Study of Albumin Bound Paclitaxel With 5-FU and CF as Second Line in Taxanes Naive Advanced Gastric Cancer
Phase 2UnknownSun Yat-sen University
0
impact